- Home
- HIND vs ENLV Comparison
HIND vs ENLV Comparison
Compare HIND & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIND | ENLV |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 26.6M |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | HIND | ENLV |
|---|---|---|
| Price | $2.70 | $1.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | N/A | ★ 461.1K |
| Earning Date | N/A | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.66 |
| 52 Week High | N/A | $2.10 |
Technical Indicators
Market Signals| Indicator | HIND | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 60.83 |
| Support Level | $3.00 | $0.85 |
| Resistance Level | $3.30 | $1.03 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 0.00 | 91.89 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.